Mitocans: Mitochondrially Targeted Anti-cancer Drugs

No Thumbnail Available
File version
Author(s)
Boukalova, Stepana
Rohlenova, Katerina
Rohlena, Jakub
Neuzil, Jiri
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)

Paulo J. Oliveira

Date
2018
Size
File type(s)
Location
License
Abstract

Mitochondria are intriguing organelles that are inherently present in most eukaryotic cells, with notable exceptions. They undertake multiple vital functions in a cell, including energy conversion, metabolite synthesis, regulation of the cellular redox state, production of reactive oxygen species, initiation of apoptosis, and buffering cellular Ca2+. Although aberrant, mitochondria are indispensable in malignant cells for critical involvement in synthesis of vital precursors for a variety of metabolic pathways. Therefore, mitochondria have recently emerged as plausible, as yet underexploited targets for cancer therapy. Here we discuss why mitochondria may be clinically relevant anti-cancer therapeutic modalities and give examples of agents that act via mitochondria that we, collectively, refer to as mitocans. Some of these agents hold a great promise for making it to the ‘bedside’, entering clinical trials.

Journal Title
Conference Title
Book Title

Mitochondrial Biology and Experimental Therapeutics

Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Other biomedical and clinical sciences not elsewhere classified

Other health sciences not elsewhere classified

Persistent link to this record
Citation
Collections